Noble laureate in Physiology/Medicine (1975) Prof. David Baltimore, fromCalifornia Institute of Technology, California, USA, had reported in the July 8, 2014 issue of the Journal “Blood” that:“Dual mechanisms by which MiR-125b represses IRF4 to induce myeloid/B-cellleukemias.”

What we say:

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived therapy for Human Leukemias: Neo-tanshinlactone D-ring, isolated from Salvia miltiorrhiza,one of the main components of feverfew, suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4

From Research findings to Therapeutic opportunity:

This study suggests that Neo-tanshinlactone D-ring, by increasing the expression of its target gene, it may increase the expression of a number of tumor suppressor genes, including IRF4. Thereby, it could inhibit the progression of B-Cell and myeloid leukemias (fig. 1).

[easy_payment currency=”USD”]

Taken together, this study suggests that pharmacological formulations encompassing “Neo–tanshinlactone D-ringor itsanalogues or Neo-tanshinlactone D-ring in combination with other anticancer drugs“may be used to inhibit B-Cell and myeloid leukemias.